ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Hospital Acquired and Community Acquired MRSA in GI Lab

This study is not yet open for participant recruitment.
Verified by Indiana University, July 2008

Sponsored by: Indiana University
Information provided by: Indiana University
ClinicalTrials.gov Identifier: NCT00577343
  Purpose

Hospital acquired and community acquired methicillin resistant staph aureus (MRSA) has become an important health issue for in recent years. Up to two thirds of patients that are hospitalized may be colonized with MRSA. The prevalence in the community is also on the rise and affects the young and healthy. It is unclear what the true prevalence of MRSA is in our own hospital and outpatient setting. This information would be relevant to how healthcare staff adhere to contact and universal precautions. : The purpose of this study is to determine the prevalence of MRSA in patients that have gastrointestinal endoscopy and endoscopic ultrasound.


Condition
Hospital Acquired MRSA
Community Acquired MRSA

ChemIDplus related topics:   Methicillin    Methicillin sodium   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Cohort, Prospective
Official Title:   Hospital Acquired and Community Acquired Methicillin Resistant Staph Aureus in the Outpatient Gastrointestinal Lab: A Prospective Study of Prevalence

Further study details as provided by Indiana University:

Primary Outcome Measures:
  • The objective of this prospective study is to identify the prevalence of MRSA in patients that use the Indiana University GI lab. [ Time Frame: less than one year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Biospecimen Description:

buccal swab for saliva


Estimated Enrollment:   1000
Study Start Date:   April 2009
Estimated Study Completion Date:   December 2010
Estimated Primary Completion Date:   December 2010 (Final data collection date for primary outcome measure)

  Eligibility
Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample

Study Population

gastrointestinal lab of oupatient and inpatients


Criteria

Inclusion Criteria:

  • No evidence of dementia or altered mental status that would prohibit the giving and understanding of informed consent, and no evidence of psychiatric risk that would preclude adequate compliance with this protocol.

Subjects must provide signed written informed consent.

Exclusion Criteria:

  • Inability to provide written informed consent.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00577343

Contacts
Contact: Michelle Symms, MSN     317-278-8223     msymms@iupui.edu    

Locations
United States, Indiana
Clarian/Indiana University Hospital     Not yet recruiting
      Indianapolis, Indiana, United States, 46202

Sponsors and Collaborators
Indiana University
  More Information

Responsible Party:   Indiana University ( Dr. Julia LeBlanc )
Study ID Numbers:   0705-31
First Received:   December 19, 2007
Last Updated:   July 15, 2008
ClinicalTrials.gov Identifier:   NCT00577343
Health Authority:   United States: Institutional Review Board

Study placed in the following topic categories:
Methicillin

ClinicalTrials.gov processed this record on August 29, 2008

U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act
U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services



Links to all studies - primarily for crawlers